We used breast cancer because MMP inhibitor treatments provided no benefit in both early and late stages and even the positive responses to VEGF inhibition found in metastatic colorectal or lung cancer were not matched in metastatic breast cancer [50, 51]. Here, VEGFA is linked to breast carcinoma.